



## OncoBioPharm secures further funding for the development of Tensinomab®.

Edinburgh, Scotland. 20th December 2015.

Scottish biotechnology company OncoBioPharm Limited announced today that it has completed a financing round to expedite the ongoing development of Tensinomab®, a novel antibody which has been shown to block cancer cell growth, invasion and metastasis in a variety of tumour models.

The funding will allow OncoBioPharm to prepare for the first clinical trial of Tensinomab, to expand its core capabilities and to drive value-creating strategies for intellectual property and collaborations.

OncoBioPharm's Chairman, Professor Christopher Wood, said: "*Tensinomab has the potential to become a major new cancer therapy and this funding is vital for the continued development of our innovative antibody.*"

### About OncoBioPharm

OncoBioPharm Ltd is a biotechnology company based in Scotland, developing therapeutic antibodies that target novel pathways associated with cancer cell growth and metastasis. These new targets provide OncoBioPharm with the potential to develop new powerful anti-cancer agents, with a focus on extending and improving the lives of people with cancer.

### About Tensinomab

Tensinomab, a single chain fragment variable of a monoclonal antibody, specifically targets the N-terminus of the angiotensin II Type 1 (AT1) receptor. Many major cancers over-express the AT1 receptor, which is associated with cancer cell proliferation, tumour invasion and metastasis. Tensinomab has been shown to block cell growth, invasion and metastasis in a variety of tumour models.